Phase 2 Stomach Cancer Trial, Recruiting NCT07026149 Sponsor: Ruijin Hospital Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT07026149
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with stomach or gastroesophageal junction (the area where the food pipe meets the stomach) cancer that has not yet been treated, where the cancer has grown into nearby tissue and spread to lymph nodes but not to other parts of the body
  • People who are planning to have surgery after receiving chemotherapy before the operation
  • People who are generally able to carry out daily activities with little or no difficulty (confirm with trial site for exact fitness level required)
  • People whose major organs such as the liver, kidneys, and blood cells are working well enough to take part (confirm with trial site for exact requirements)
  • People who are expected to live for more than 12 months
  • People who are able and willing to use a reliable method of contraception during the study and for 120 days after the last dose of treatment (applies to both male and female participants who are able to have children)

Who may not be able to join:

  • People with high blood pressure that remains uncontrolled even with blood pressure medication
  • People who have a known severe allergy or reaction to any of the medications used in the study
  • People who have a known condition, either inherited or developed, that affects blood clotting or increases the risk of bleeding or clots
  • People who have a known condition that significantly weakens the immune system, such as HIV infection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-021-64370045

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
8 June 2025
Est. completion
1 September 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathological Complete Response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov